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Research in the field of protein therapeutics has exploded over the past decade and 
continues to grow in both academia and in industry.  Protein drugs have advantages of 
being highly specific and highly active making them coveted targets for high profile 
disease states like cancer and multiple sclerosis.   Unfortunately, their many advantages 
are complemented by their obstacles.  Because proteins are highly active and highly 
specific, the window between efficacy and toxicity is very narrow and drug development 
can be long and arduous.  In addition, protein activity is dependent on its specific folding 
conformation that is easily disrupted by a variety of development processes.  This 
research aimed to identify microparticle formulations to control protein release and also 
to determine which formulation parameters affected burst release, encapsulation, and 
steady-state release the most.  It was found that polymer type and composition were 
two of the most important factors.  Long-term controlled release of bovine serum 
albumin (BSA) was achieved as well as a wide variety of release profiles.  A method was 
identified for micronizing protein at low cost to retain activity and coacervation was 
evaluated as a method for preparing protein loaded microspheres.  This research 
ix 
provides a basis from which researchers can create better controlled release 
formulations for future protein therapeutics.   
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CHAPTER 1. INTRODUCTION 
1.1 Introduction 
The field of protein therapeutics is one that is growing quickly.  Extensive research 
is being conducted at micro and macro levels in both industry and academia.  The future 
of protein therapeutics is bright due to a variety of scientific and consumer-driven 
factors.  In comparison to small molecule drugs, protein therapeutics exhibit several 
distinct advantages.  Firstly, proteins are highly specific and their individual functions 
cannot be duplicated by small molecules1.  Secondly, proteins are less likely to cause 
effects outside of their explicit function due to high specificity2. The combination of 
these two factors make proteins very attractive for treatment of complex, site specific, 
diseases like cancer and multiple sclerosis3.  Thirdly, many proteins are produced 
naturally and, thus, are less likely to elicit an adverse immune response.  Fourth, protein 
activity is often stronger than that of a small molecule drug, making dosing 
requirements much lower.  Finally, because proteins are so specific, and require such 
fine tuning, the process for generic drug development is much more involved, expensive, 
and time consuming4,5,6,7.  Thus, market exclusivity is often longer for protein 
therapeutics than for small molecule drugs for which bioequivalence is easier to 
accomplish.  These factors have led to greater industry interest in protein therapeutics 
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over the past decade.  In 2012, protein therapeutics accounted for 5 of the top 10 selling 
drugs globally and 54% of sales8.  
 
In spite of all of the advantages that protein therapeutics provide, proteins also 
come with their share of obstacles.  In general, most therapeutic proteins have a high 
level of activity.  That is, when they are bound to the correct binding site, they can have 
a profound and potent effect.  However, this activity can often be easily disrupted upon 
the unfolding of the protein.  The activity of proteins is directly tied to their shape and 
conformation.  Unfolding of a protein can occur due to exposure to heat, ionic forces, 
exposure to a water-oil interface, organic solvent, or radiation9,10,11,12. This makes 
protein encapsulation especially difficult compared to small molecule drugs.  Also, most 
protein-based drugs must be administered via injection due to their susceptibility to 
enzymatic degradation, molecular size, and charge issues that limit their bioavailability13. 
Delivery by injection is difficult for formulators because standard techniques for 
controlling small molecule drug release for oral delivery cannot be directly applied.  
Therefore, to improve protein drug delivery, formulators commonly use PEGylation, 
liposomes, and biodegradable microspheres14.  Finally, due to their high levels of activity, 
protein drugs often have narrow therapeutic windows.  That is, dosing must be tightly 
controlled in order to maintain therapeutic effects and avoid toxic effects.  
PLGA microspheres are often used to try to control protein release for injectable 
formulations15.  This is an attractive approach because PLGA is biocompatible, 
biodegradable, and can be modified to obtain various release profiles16.  By modifying 
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properties like molecular weight, ratio of lactide to glycolide, and drug concentration, 
researchers have attempted to control and extend protein release17,18,19,20.  This 
research has broad applicability for drug development.  Unfortunately, organic solvents 
are often involved in microsphere fabrication which can easily denature proteins if 
directly exposed.  Denaturation often occurs when aqueous protein interacts with 
water-miscible solvents or has direct exposure to a water-oil interface.  These situations 
are common in conventional microsphere fabrication.   
To prevent water-solvent interactions, some groups have suspended micronized 
solid protein in polymer solution20,21,22.  This often takes the form of a solid-in-oil-in-
water (S/O/W) emulsion.  It is well documented that in the solid state, protein stability 
increases dramatically23.  Micronization of protein is crucial to solid-in-oil suspensions 
for favorable release from microspheres.  In general, micronized protein particles allow 
for more uniform dispersions and thus, more consistent release.  Research groups have 
attacked the problem of protein micronization from a variety of angles including 
precipitation, sieving, spray drying, supercritical fluid technology, milling, and high 
pressure homogenization among others24,25,26,27,28,29.   Some of these methods can 
output protein particles below 50µm while others can output particles below 500nm.  
However, techniques that produce submicron or sub 10µm sized particles are very 
expensive and often require many additives and excipients, making them less than ideal.  
Researchers in the protein drug delivery field would benefit from a low-cost, effective, 
micronization system that would allow for uniform dispersions with retained activity.   
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The main purpose of this research was to address a variety of needs in the 
aforementioned areas in order to, ultimately, be able to control therapeutic protein 
release.  This was done, firstly, by evaluating the effects of common formulation 
parameters on protein release and encapsulation.  BSA was encapsulated in 
microparticles fabricated using a method previously published in our laboratory30.  The 
value of this release study was in its sheer magnitude and breadth.  Because our 
laboratory has experience with polymer synthesis and with protein delivery, it was 
possible to evaluate many formulation parameters in more detail than previous related 
studies.  The ability to choose input formulation parameters in order to create a 
predictable release profile would be a major milestone in protein release and 
microparticle technology and is the focus of this study.   
The second goal of the research was to identify a technique to micronize lyophilized 
protein at low cost to a size suitable for microencapsulation. Ideally this would eliminate 
the need to spend thousands of dollars to obtain useful protein powder.  This work 
summarizes a bench-made ball-grinding method and the parameters that affected the 
final particle size.   
The final goal of this work was to study the coacervation technique as it relates to 
controlled protein release.  A variety of process parameters were varied in order to 
identify which of them had profound effects.  This portion of the research stemmed 
from the need to develop very low burst, high encapsulation formulations.  The findings 
presented in this work will, hopefully, aid future researchers in achieving their goals in 
the field of controlled delivery of therapeutic proteins.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Fabrication Overview 
All microparticles were fabricated using a modified version of a hydrogel template 
method30.  In this method, water soluble templates made from polyvinyl alcohol (PVA) 
were used for microfabrication.  The PVA templates were made through a series of 
photolithography and molding techniques in which they were patterned with an array of 
50µm wells.  After the PVA templates were made, the wells were filled with a 
predetermined polymer-BSA solution and allowed to dry.  The dry microparticles were 
collected by dissolution of the PVA template in deionized water (DW) and rinsing.  
Microparticles were then freeze-dried prior to testing. Error! Reference source not 




Figure 1: Hydrogel template method for microparticle fabrication31. 
 
2.1.1 Templates 
Firstly, a 3 inch silicon wafer (University Wafer) was coated with SU-8 2025 
photoresist (MicroChem) using a spin coater (Specialty Coating Systems™ G3P-8).  
Photoresist was spun at 2200 rpm to create a layer of approximately ~35µm.  The wafer 
was then baked at 85 °C for 15 minutes to dry. In order to obtain a total thickness of 
~70µm, a second layer was added and dried by the same process.  Using a mask aligner 
(Karl Suss®: MJB3), the coated wafer was exposed to UV for 30 seconds with a patterned 
mask in place in order to initiate crosslinking of the photoresist.  The coated wafer was 
then baked at 85 °C for 15 minutes to finish the crosslinking process.  Uncrosslinked 
areas were removed by sonication (Branson® 5200) for 6.5 minutes in SU-8 developer 
solvent (MicroChem).  The wafer was rinsed with isopropyl alcohol and dried with 
pressurized nitrogen.  Finally, the patterned wafer underwent a hard bake at 200 °C for 
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2 minutes to remove micro cracks in the photoresist. Figure 2 below is a schematic of 
the pattern used to make cylindrical wells in the coated silicon wafer.   
 
 
Figure 2:  Template pattern size and spacing 
 
Molds of the silicon wafer template were made from polydimethysiloxane 
(PDMS) (Sylgard® 184 Silicone Elastomer Kit) and acted as an intermediate step towards 
the water-soluble PVA templates.  The 3 inch silicon wafer template was glued onto a 4 
inch square sodalime glass plate and placed in a ceramic pan.  Next, 60mL of 
uncrosslinked PDMS was mixed with 6 mL of crosslinking agent and poured over the 
silicon wafer template.  The pan was then degassed under vacuum for 15 minutes and 
placed in an oven at 60 oC for 2 hours to crosslink the PDMS.  The pan was removed 
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from the oven and allowed to cool for 10 minutes before peeling the flexible PDMS 
mold from the surface of the patterned silicon wafer template.  The finished PDMS 
molds had 70µm cylindrical pillars with 50µm diameter.   
Water-soluble PVA templates were made by creating a cast of the intermediate 
PDMS mold.  By casting around the 70µm pillars, after drying, PVA templates contained 
~50µm wells for microparticle fabrication.  To create the PVA templates, 2.67% PVA was 
dissolved in 67% ethanol.  4mL of PVA solution was poured over the PDMS template and 
dried at 60 °C for 2 hours.  Dry PVA templates were then peeled from the surface of the 
PDMS and stored at room temperature in a desiccated chamber. 
 
2.1.2 BSA Precipitation: ZnCl2 and Acetone 
A predetermined amount of ZnCl2 at 10% (wt/vol) in DW was added by pipet to 
the BSA at 75mg/mL in deionized while vortexing.  After addition of ZnCl2, acetone was 
added while vortexing at a ratio of 6:1 acetone to precipitate solution.  After 30 seconds 
of vortex mixing, the solution was centrifuged at 3100 rpm for 1 minute and the 
supernatant was removed.  Acetone addition, vortexing, centrifugation, and 
supernatant removal were repeated to ensure nearly 100% BSA precipitation.    
2.1.3 BSA Precipitation: ZnCl2 Only 
A solution was made to contain 50mg/mL of PVP (MW 58,000) and 75mg/mL 
solid powder BSA in DW.  While vortexing or slow stirring (method dependent), a 
predetermined amount of ZnCl2 at 10% (wt/vol) was added by pipet to precipitate the 
BSA.  Vortexing and stirring continued for 1 minute after precipitation to allow for 
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sufficient mixing.  Next, vortexed solutions were frozen at -80 °C for 2 hours prior to 
freeze drying.  Slow stirred solutions were transferred to a conical tube and centrifuged 
at 3100 rpm for 1 minute and the supernatant removed and poured back into the 
precipitation beaker.  Another aliquot of ZnCl2 solution was added to the supernatant to 
ensure nearly 100% precipitation.  This solution was added to the conical tube and 
centrifuged at 3100 rpm for 1 minute and the supernatant was removed.  The 
concentrated precipitate was frozen at -80 °C for 2 hours prior to freeze drying.  All 
samples were freeze-dried (Labconco® Freezone 4.5) and kept frozen at -20 °C until used 
in the formulation. 
 
2.1.4 Polymer-Drug Solutions 
All polymers were obtained from Akina Inc. or were synthesized as described 
below.  Polymers used for microparticles were PLGA, PDLLA, and PLLA of varying lactide: 
glycolide ratios (L:G), end-caps, and molecular weights.  All reported molecular weights 
are weight average (MW) determined by gel permeation chromatography (GPC).  
Lactide: glycolide ratios were reported as averages determined by nuclear magnetic 
resonance (NMR).   
The first method for mixing polymer-BSA solutions was for the acetone 
precipitated protein.  Firstly, polymer solutions were prepared by dissolving PLGA, 
PDLLA, or PLLA into organic solvent.  Organic solvents included dichloromethane (DCM), 
1,4 dioxane (DX), ethyl acetate (EA), acetonitrile (ACN), and benzyl alcohol (BA).  Dry 
polymer was weighed into a 15mL conical tube at a predetermined concentration 
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(wt/vol) and organic solvent was added to bring the solution to approximately 80% of 
the final volume.  This solution was then added to the BSA precipitate by vortex mixing.  
Organic solvent was then added to bring the solution to the final volume.     
The second method for mixing polymer-BSA solutions was for the dry-ground 
protein which was precipitated with ZnCl2 only.  First, dry BSA powder and polymer 
were weighed at predetermined concentrations into the same 15mL tube.  Next organic 
solvent was added to bring the solution to the proper final volume.  The solution was 
then mixed by vortex for 1 minute.   
 
2.1.5 Microparticle Fabrication 
Using premixed polymer-drug solutions.  Microparticles were fabricated by filling 
the premade PVA templates according to a method previously published by our group30.  
After drying for at least 10 minutes, the filled PVA templates were dissolved in 35mL of 
deionized water and allowed to shake at 37oC for 30 minutes.  The free microparticles 
were then collected by filtering through nylon mesh and centrifugation.  They were 
washed in 35mL of deionized water for 5 minutes and were collected again.  Finally, all 
microparticles were frozen and lyophilized prior to testing.   
2.2 Polymer Synthesis 
For polymer compositions and MWs that could not be readily obtained from Akina 
Incorportated, polymers were synthesized according to a previously published ring-
opening polymerization method32.  Copolymers of PLLA and PDLLA were synthesized as 
both random chains and block copolymers.  The two syntheses were done by addition of 
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equal quantities of L and D,L lactide monomers or equal quantities of known MW 
polymers, respectively.   
 
2.3 BSA In-Vitro Release  
After lyophilization, microparticles were weighed into 1.5mL centrifuge tubes and 
dispersed in 1mL of phosphate buffered saline with .05% Tween® 20 (PBST) at pH 7.4 for 
BSA release analysis.  All samples were incubated at 37 oC and shaken at approximately 
60 rpm between time points.  At predetermined time points, samples were centrifuged 
and the supernatant was collected for BSA release analysis.  All samples were vortexed 
before and after supernatant collection.  Finally, 1mL of fresh PBST was added before 
returning to incubation.  All formulations were run with either duplicate or triplicate 
samples.   
All BSA release samples were analyzed using the bicinchoninic acid (BCA) assay or 
Micro BCA assay (Pierce™).  For every time point, the amount of BSA released was 
determined by comparison to a standard curve of known concentration in PBST.  In 
order to determine the BSA encapsulation before release and the residual BSA at the 
end of the study, lyophilized microparticles were dissolved in 1mL of DX and centrifuged.  
The DX supernatant was removed and 1mL of 0.05M sodium hydroxide (NaOH) was 
added to dissolve the remaining BSA. Samples were then analyzed using the BCA assay 
and compared to a standard curve of known concentrations in 0.05M NaOH.  
Encapsulation analysis was conducted on duplicate or triplicate samples for all 
formulations.  For BSA release samples, encapsulation was estimated using the average 
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encapsulation from encapsulation samples.  Residual BSA analysis was done either after 
all particles were clearly dissolved in PBST or after 540 days.   
 
2.4 Coacervation 
Coacervation microparticles were made according to a process similar to those 
previously published33,34, 35,36.   Ball-ground BSA and preselected polymer were weighed 
into a conical tube at a ratio of 1:1 to which DCM was added.  The solution was then 
homogenized for 1 minute at 17,500 rpm using a probe homogenizer in order to break 
up BSA aggregates (Ultra Turax® T25 Basic).  Silicone oil (SO) was added to the polymer-
BSA solution according to the published methods to create coacervated microspheres.  
The microspheres in silicone oil were dumped into 100mL of cold hexane to harden for 6 
minutes.  They were then collected by centrifuge and washed twice with 35mL of 
hexane to remove remaining silicone oil.  Finally, all microspheres were lyophilized 
overnight before encapsulation and release analysis.   
 
2.5 BSA Micronization 
2.5.1 Ball Grinding 
A predetermined quantity of freeze-dried BSA precipitate was weighed into a 
polytrifluoroethylene (PTFE) grinding jar or an agate grinding jar.  The grinding jar was 
then charged to approximately 55% of its total volume with zirconia grinding balls of 
2mm or 0.5mm diameter.  The jar was then sealed and placed inside of a rotating tube 
set at a predetermined speed using a brushless motor and controller (Vexta BLFD Series).   
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Grinding proceeded for 24 to 72 hours.  Ground BSA was sifted through a 425µm sieve 
to collect the micronized powder.  The rotating assembly and motor are shown in Figure 
3 below.   
 
 
Figure 3: Ball grinding assembly and motor 
 
2.5.2 Mortar and Pestle Grinding 
Approximately 300mg of freeze-dried BSA precipitate was weighed into an agate 
mortar and pestle and ground for 5 to 15 minutes.   For some samples, 100µL of DX was 
added to the mortar and pestle and ground with the BSA precipitate for 2-5 minutes or 
until most of the DX had evaporated and the BSA powder was dry and fluffy.  This 
process was repeated.  After BSA was dry and fluffy a second time, it was collected into 
a conical tube and 7mL of DCM was added and the tube was vortexed for 30 seconds.  
The suspension was centrifuged at 3100rpm for 2.5 minutes and the supernatant was 
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removed before freeze-drying overnight.  After freeze-drying, the BSA powder was 





CHAPTER 3. RESULTS 
3.1 BSA Release Study 
A large series of experiments were designed, including over 70 microparticle 
formulations, to determine the major effects of common formulation parameters on 
protein release and encapsulation.  Seven input parameters, including polymer MW, 
polymer type, L:G ratio, polymer concentration, BSA concentration, solvent, and end cap 
type were evaluated by four output parameters; total BSA release, burst release, 
encapsulation efficiency, and plateau phase release rate.  Formulations were also 
observed qualitatively regarding particle aggregation and release profile shape.   
 
3.1.1 Poly(L-lactide) and Poly(D,L-lactide) Formulations 
A series of microparticle formulations were fabricated in order to evaluate the 
BSA release properties of poly(L-lactide) (PLLA) and poly(D,L-lactide) (PDLLA).  A total of 
21 formulations were tested; 10 PLLA and 11 PDLLA.  Polymer molecular weight (MW), 
polymer concentration, solvent, and BSA concentration varied for each formulation.  
Table 1 shows all of the formulations.  Molecular weights ranged from 3 kiloDaltons 
(kDa) to 230 kDa which covers nearly the effective range of dissolution for DCM. 
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Polymer concentration for each formulation was selected to allow for manageable 






Table 1: PLLA and PDLLA Formulations 
 
 Formulation Polymer MW (kDa) % Polymer (wt/vol) % BSA (wt/wt) 
Encapsulation 
Eff. (%) Solvent 
12007M PLLA-C18 197 15 10 115.1 DCM 
12008M PLLA-C18 95 15 10 102.9 DCM 
12004M PLLA-COOH 230 10 10 102.5 DCM 
12003M PLLA-COOH 180 10 10 100.9 DCM 
12001M PLLA-COOH 61 25 10 95.0 DCM 
12006M PLLA-C18 57 25 10 90.1 DCM 
12005M PLLA-C18 33 40 10 87.2 DCM 
12002M PLLA-COOH 91 25 10 86.9 DCM 
12013M PLLA-COOH 20 25 10 77.2 DCM 
12014M PLLA-C18 3 40 10 40.0 DCM 
12031M PDLLA-COOH 173 13.5 10 126.6 DCM 
12032M PDLLA-COOH 200 13.5 10 110.4 DCM 
12015M PDLLA-COOH 102 20 10 107.8 DCM 
12011M PDLLA-COOH 173 13.5 10 98.1 DCM 
12009M PDLLA-COOH 200 13.5 10 96.9 DCM 
12038M PDLLA-COOH 66 25 20 91.3 DCM 
12030M PDLLA-COOH 66 25 10 83.1 DCM 
12041M PDLLA-COOH 66 25 10 78.8 DX 
12048M PDLLA-COOH 82 19 20 72.5 DCM 
12049M PDLLA-COOH 82 19 20 65.5 DX 
12010M PDLLA-COOH 18 45 10 44.8 DCM 
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Figure 4 below shows the 540 day release data for all PLLA and PDLLA formulations.    
From the data, it is clear that PLLA formulations released less BSA than PDLLA with the 
exception of the PLLA with MW 3 kDa (12014M).   All other PLLA formulations showed 
less than 18% burst release, with the maximum and minimum being 17.3% (12004M) 
and 5.5% (12001M), respectively.  Burst release was defined as the total release after 3 
days.  In addition, no PLLA formulation, besides 12014M, released more than 39% 













































In contrast, PDLLA formulations had higher burst and total release than PLLA and 
had a wider variety of release profiles (Figure 5). Burst release for PDLLA formulations 
ranged from 16.7% (12049M) to 84.8% (12010M) with total release ranging from 100% 
(12010M) to 44% (12049M).  Formulations with polymers under 20 kDa showed notably 
higher burst release and less predictable plateau phases for both PLLA and PDLLA.  















































The BSA encapsulation efficiency for PLLA formulations was close to 100% for 
most formulations.  The maximum was 115% (12007M) and the minimum was 40% 
(12014M).  The average encapsulation efficiency for PLLA formulations was 90%±20%.  
Formulations with a MW of 20kDa or below averaged 59%±26%.  All other formulations 
(MW 38k and above) averaged 98%±26%.  Encapsulation efficiencies for PDLLA 
formulations were similar to PLLA formulations with an average encapsulation efficiency 
of 89%±23%.  One PDLLA formulation had a MW below 20kDa (12010M) and had a 
encapsulation efficiency of 45%.  The average encapsulation efficiency for all other 
formulations was 93%±19%.   
For both polymer types, burst release of BSA was followed by a nearly zero-order 
plateau phase.  Exceptions include PLLA 3k and PDLLA 18k.  PLLA formulations reached 
their plateau phase after approximately 7 days and continued zero-order release until 
the end of the study.  PDLLA formulations, in contrast, took approximately 28 days to 
plateau, but they also continued zero order release until the end of the study.  The 
average linear release rates during plateau phases were higher for PDLLA formulations 
than PLLA formulations at 0.19%±0.08% per week and 0.12%±0.05% per week, 
respectively.  All R-squared values were greater than 0.96 for linear phases.   
Two polymer end cap types were evaluated for PLLA formulations including 
carboxylic acid (COOH), and oleic acid (C18).  No notable differences in BSA release or 
encapsulation were noted for either end cap.  Thus, polymers in subsequent 
formulations all had COOH end caps as polymers of this type are more readily available 
and are less difficult to synthesize.   
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3.1.2 PLLA: PDLLA Hybrid Formulations 
In order to observe the effects of hybrid formulation, a series of 6 PLLA-PDLLA 
mixtures and copolymer formulations were tested for BSA release.  Four of the 
formulations; 12018M, 12017M, 12019M, and 12020M, contained synthesized polymers 
with random blocks of L-lactide and D,L-lactide.  Formulation 12021M contained a block 
copolymer synthesized from PLLA (61 kDa) and PDLLA (66 kDa) and 12022M contained a 
physical mixture of the same aforementioned polymers.  Table 2 below details all of the 
hybrid formulations.  Polymer concentration was varied for random copolymers for 
comparison purposes.  Polymer concentration was varied for random copolymers for 





















Eff. (%) Solvent 
12018M PLLA-PDLLA-C18 (Random) 111 12 10 83.7 DCM 
12017M PLLA-PDLLA-COOH (Random) 72 12 10 78.1 DCM 
12019M PLLA-PDLLA-C18 (Random) 111 25 10 70.9 DCM 
12022M 
PLLA-PDLLA-COOH (physical 
mixture) 61/66 25 10 61.3 DCM 
12020M PLLA-PDLLA-COOH (Random) 72 25 10 64.0 DCM 
12021M PLLA-PDLLA-COOH (Block) 72 25 10 63.2 DCM 
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The full 540 day release data is represented in Figure 1: BSA release for PLLA: 
PDLLA hybrid formulations.  Burst release ranged from 65.9% to 10.7% for 12018M and 
12021M, respectively.  Total release ranged from 100% to 69.3% in 12018M and 
12021M, respectively.  Four of the formulations (12019M, 12022M, 12020M and 1202M) 
exhibited similar release properties with similar burst and plateau phases while 12018M 
and 12017M exhibited notably higher burst and total release.  Both 12018M and 
12017M were random copolymers with only 12% polymer.  For both polymers, their 25% 











































Three of the hybrid formulations exhibited a linear plateau phase.  Formulations 
12020M and 12021M reached their linear phase after 28 days and 12019M reached it 
after 42 days.    All three maintained linearity to the end of the study.  The average 
release during the linear phase was 0.4%±0.09% per 7 days.  The minimum and 
maximum release rates were 0.33% (12020M) and 0.51% (12021M) 7 days, respectively. 
Average release rate for PLLA: PDLLA hybrid formulations is double the average linear 
release of PDLLA which is nearly twice that of PLLA.  
 
3.1.3 PLGA Formulations 
Fifty PLGA formulations were made for BSA release analysis.  Again, many 
formulation properties were varied to observe their effects.  Table 2 below includes all 
formulations in full detail.  Molecular weights ranged from 3kDa to 150kDa.  Other 




Table 2: PLGA formulations 






Eff. (%) Solvent 
12024M PLGA-COOH 38 26 10 87.7 DCM 
12023M PLGA-COOH 17 40 10 51.0 DCM 
12035M PLGA-COOH 66 25 20 86.3 DCM 
12056M PLGA-COOH 107 11 20 75.7 DCM 
12066M PLGA-COOH 120 12 20 89.3 DCM 
12070M PLGA-COOH 38 21 20 73.3 DX 
12046M PLGA-COOH 50 20 20 83.7 DCM 
12074M PLGA-COOH 38 21 20 75.8 3:1 EA:BA 
12055M PLGA-COOH 120 16.4 20 83.3 DCM 
12026M PLGA-COOH 66 25 10 73.3 DCM 
12068M PLGA-COOH 120 21 20 79.2 ACN 
12069M PLGA-COOH 38 21 20 77.1 DCM 
12047M PLGA-COOH 40 20 20 96.4 DCM 
12075M PLGA-COOH 38 21 20 77.5 1:3 EA:BA 
12045M PLGA-COOH 54 20 20 75.8 DCM 
12036M PLGA-COOH 120 23 20 101.0 DCM 
12063M PLGA-COOH 73 25 20 124.2 DCM 
12073M PLGA-COOH 38 21 20 81.6 1:1 EA:BA 
12071M PLGA-COOH 38 21 20 85.0 BA 
12027M PLGA-COOH 107 14 10 62.2 DCM 
12033M PLGA-COOH 17 40 20 24.0 DCM 
12058M PLGA-COOH 73 4 20 115.1 DCM 
12061M PLGA-COOH 73 18 20 111.5 DX 
12016M PLGA-COOH 3 35 10 43.9 DCM 
12072M PLGA-COOH 38 21 20 92.3 EA 
12059M PLGA-COOH 73 11 20 118.9 DCM 
12037M PLGA-COOH 150 11 20 81.4 DCM 
12076M PLGA-COOH 38 21 20 94.7 ACN 
12067M PLGA-COOH 120 12 20 76.4 DX 
12060M PLGA-COOH 73 18 20 128.9 DCM 
12028M PLGA-COOH 120 23 10 107.8 DCM 
12062M PLGA-COOH 73 18 20 118.4 ACN 
12065M PLGA-COOH 17/120 30 20 106.3 DCM 
12043M PLGA-COOH 55 11 30 112.7 DCM 
12025M PLGA-COOH 55 30 10 78.3 DCM 
12039M PLGA-COOH 107 10 10 88.7 DX 
12012M PLGA-COOH 150 9 10 97.6 DCM 
12029M PLGA-COOH 150 11 10 81.1 DCM 
12057M PLGA-COOH 55 30 20 82.0 DCM 
12054M PLGA-COOH 150 9 20 102.0 DCM 
12034M PLGA-COOH 55 30 20 84.8 DCM 
12044M PLGA-COOH 55 17.6 10 66.1 DX 
12040M PLGA-COOH 150 10 10 97.3 DX 





Figure 2 shows the release data for the 540 day study.  Release data were 
collected until all of the microparticles were dissolved in a given sample.  Thus, some 
samples did not release for 540 days.  The PLGA formulations exhibited a wide variety of 
release profiles.  Burst release ranged from 6.6% (12044M) to 95.9% (12024M) and total 


























































BSA encapsulation varied greatly among PLGA formulations.  The maximum 
encapsulation efficiency was 129% (12060M) and the minimum encapsulation efficiency 
was 24% (12033M).  The average encapsulation efficiency for all formulations was 
87%±20%.  Formulations with PLGA of MW less than 20kDa averaged notably less 
(40%±14).  All other formulations (MW above 38kDa) averaged 91%±16% encapsulation 
efficiency.  No other trends were observed regarding the BSA encapsulation in PLGA 
microparticles.   
Ten of the 44 PLGA formulations exhibited a linear plateau phase.  Most of the 
formulations reached their plateau phases within the first 28 to 42 days.  All but one 
(12028M) had a L:G monomer ratio of 85:15.  Linear release rates ranged from 0.10%   
(12034M, 12057M) to 0.38% per 7 days (12028M).  The average linear release rate was 
0.25%±0.11% per 7 days for all 10 formulations.  Linear release rate was, on average, 
higher for PLGA formulations than PLLA and PDLLA formulations but lower than the 
PLLA: PDLLA copolymer formulations.   
For each formulation, the L:G ratio was predetermined.  There was no statistical 
difference between the average release of 50:50, 60:40, and 75:25 L:G ratios.  However, 
formulations with L:G ratio of 85:15 had statistically smaller average burst release 
(34.5%) and total release (55.2%) than the other formulations.  In addition, all but one 
85:15 formulation exhibited a linear plateau phase as opposed to one 50:50 formulation 
and none of any other composition.   
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3.1.4 DCM vs. 1,4 Dioxane 
To evaluate the effect of solvent on the release of BSA, a series of microparticles 
were fabricated according to the recipes shown in Table 3.  For this study, three 
polymers were chosen based on favorable release characteristics that were previously 
evaluated.  The first was PDLLA and the second and third were both PLGA with different 
molecular weights.  It is important to note that all other parameters were held constant 
in order to assess the effect of solvent alone.  Two microparticle formulations were 
made for each polymer using DCM for the first and DX for the second (three 
formulations for PLGA 73K).  
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Figure 3 below shows the BSA release data for all six formulations for the 540 
days or until all particles were dissolved.  For each polymer, the burst release and total 
release was higher for the DCM formulation than the DX formulation.  Three 
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formulations, 12049M, 12048M, and 12050M exhibited linear plateau regions to the 
end of the study.  
 
Figure 3: BSA Release for DX and DCM formulations 
 
3.1.5 Other Observations 
Although the polymer concentration varied for each formulation, it was not 
intended to act as a factor of comparison.  The concentration for each polymer was 
chosen based on its ability to make full, cylindrical microparticles with high yield.  In 
most instances, this meant that the solution was of a mid-range viscosity (100-1000 
centipoise).  As it was not used as an input variable, no trends in BSA release were 





































Encapsulation efficiency decreased drastically for polymers with MW below 20 
kDa.  This is true for all polymer types used in this study.  No other variables were 
observed as having notable effects on encapsulation efficiency.  In addition there was 
no trend associated with increasing MW in polymers above 20 kDa.  Polymers with 
molecular weight below approximately 40 kDa also aggregated into a single mass during 
the release study.  These formulations tended to exhibit a high burst release followed by 
a very slow linear or second order release until they dissolved, typically short of the end 
of the study. 
 
3.2 BSA Micronization 
Five grinding methods were used to obtain micronized BSA powder.  This was 
done in an effort to obtain solid form protein powder without unfolding or denaturing 
the protein.  The overall grinding processes were conducted according to the methods 



















Final BSA precipitate 
size (µm) 
GM1 Ball grinding with 2mm balls, no 
excess PVP 
48 hr 0.5-8 
GM2 Mortar and pestle, excess PVP 15 min 2-25 
GM3 Mortar and pestle, excess PVP, DX 
grind, DCM wash 
15 min 2-50 
GM4 Mortar and pestle, no excess PVP 15 min 5-70 
GM5 Ball grinding with 0.5mm balls, no 
excess PVP 
48 hr 30-250 
 
Sizes provided in Table 4 were determined by scanning electron microscopy (SEM).  
Analysis of SEM micrographs showed that grinding method 1 (GM1) yielded the smallest 
BSA precipitate size as shown in Figure 4.   GM5 resulted in the largest final precipitate 











Figure 5: SEM image of BSA powder from GM5 
 
For this method, it was clear upon gross inspection that the precipitate was actually 
smaller prior to ball grinding.  All grinding techniques utilized PVP as an additive to 
prevent aggregation during lyophilization.  However, for some methods (GM1, GM4, 
GM5) excess PVP was removed during the precipitation process by centrifugation.  This 
allowed for slightly more aggregation but also provided higher protein content in the 
final precipitate. For the other methods (GM2, GM3), excess PVP was frozen with the 










Figure 7: SEM image of BSA powder from GM3 
 
In GM3, BSA was ground in a similar way to GM2 and GM4, however, 200µl of 
DX was added in order to create a wet grinding environment and create greater shear 
forces for micronization.  After DX grinding, the BSA was washed in DCM to remove DX, 
neutralize particle interactions, and allow for better drying.  After a second 
lyophilization, GM3 BSA was ground again by mortar and pestle.  In initial tests, DX 
grinding with a DCM wash seemed to create smaller precipitate.  After controlling the 
grinding time, it was concluded that a smaller precipitate was obtained simply due to 
increased grinding time and that GM2 is a more efficient method.  Ball grinding yielded 
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smaller BSA precipitate than mortar and pestle grinding which we can see by 
comparison of GM1 and GM4 (Figure 8).   
 
 
Figure 8: SEM image of BSA powder from GM4 
 
The grinding time could have been a factor in this result but it was noted that 
after 10 to 15 minutes, BSA powder stuck to the walls of the mortar due to static forces, 
making grinding more difficult and less efficient.  In ball grinding, the similar 
phenomenon was noted as BSA powder would cling to grinding balls as well as the sides 
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of the grinding jar.  Overall, we see that grinding ball size, amount of PVP, and grinding 
time are all factors that affect the final size of lyophilized protein powder.  
 
3.3 Coacervation 
A series of microspheres were made by a coacervation method described above in 
an effort to increase drug encapsulation and decrease burst release.  Before the 
coacervation study, a series of short experiments were conducted to determine 
parameters suitable for obtaining stable coacervate.  The results of those experiments 
are not provided here as they do not affect the findings of this study. Two experiments 
were conducted in succession to determine which parameters in the coacervation 
process had the greatest effect on protein release. Table 5 outlines the details of the 
formulations for the first experiment.  




















1 500 4 2.5 700 
CF3 PLLA 100K 1 200 4 2.5 700 
CF4 PLLA 100K 1 100 4 2.5 700 
CF5 PLLA 100K 1 1000 4 2.5 700 
CF6 PLLA 100K 1 500 4 0.5 700 
CF7 PLLA 100K 1 500 4 2.5 300 
CF8 PLLA 100K 1 500 4 10 700 
CF9 PLLA 100K 2 500 4 2.5 700 
CF10 PLLA 100K 1 500 2 2.5 700 




Results of the first coacervation experiment are summarized in Table 6.  The 
main parameters that were analyzed were the total encapsulation efficiency, and 1 day 
BSA release.  The theoretical encapsulation for all samples was 50% (wt/wt).  The 
minimum 1 day release was 19.1% (CF6) and the maximum 1 day release was 55.4% 
(CF7).  The average 1 day release for all formulations was 43.4%±9.7%.  The maximum 
encapsulation efficiency was 78.0% (CF1) and the minimum encapsulation efficiency was 
63.8% (CF10).  The average encapsulation efficiency was 73.0%±5.0%.  Data analysis 
revealed that, SO viscosity, SO infusion rate, and stirring speed were possible factors 
affecting release. SO volume was the only factor that exhibited a possible effect on 
encapsulation efficiency.  These results are shown in Table 6 below.  










1000cps 36.3±2.8 73.0±1.1 
500cps 43.7±1.1 78.0±3.4 
200cps 45.4±2.0 72.8±2.6 
100cps 50.4±2.4 76.6±2.1 
SO Infusion Rate 
10mL/min 46.2±2.4 73.5±3.1 
2.5mL/min 43.7±1.1 78.0±3.4 
0.5mL/min 19.1±2.3 75.1±4.4 
Stirring Speed 
700rpm 43.7±1.1 78.0±3.4 
500rpm 52.2±2.6 67.0±4.0 
300rpm 55.4±4.4 74.6±2.4 
SO Volume 
4mL 39.6±1.1 78.0±3.4 




Based on the results from the first Experiment 1 involving CF1-CF10, Experiment 
2 was designed to try and confirm these effects, minimize burst release, and maximize 
encapsulation efficiency further.  The details of each formulation in the Experiment 2 
are outlined in Table 7 below.  All constant parameters were selected in order to 
maintain comparability with Experiment 1.  Variable parameters included SO infusion 
rate, stirring speed, and post-infusion (PI) stirring time and were selected as extensions 
of the ranges in Experiment 1.  PI stirring time was added in order to determine if the 
decrease in burst release seen in Experiment 1 due to SO infusion rate was, in fact, due 
to the extra stirring time.   
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Results of Experiment 2 are shown in Table 8 below.  For all samples in 
Experiment 2, the average encapsulation efficiency was 100.9%±8.3% which is 
significantly greater than 73.0%±5.0% from Experiment 1. However, the average 1 day 
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release for Experiment 2 was 38.7%±7.7% which is not statistically different from that of 
Experiment 1 which was 43.4%±9.7%.  In addition, the minimum 1 day releas for 
Experiments 1 and 2 were 31.4%±6.0% and 19.1%±2.3%, respectively and thus, did not 
improve in Experiment 2.  Also, in Experiment 2, no trends in 1 day release or 
encapsulation were observed in relation to input parameter variations.  The 1 day 
release at 0.1mL/min SO infusion was statistically smaller than at 0.3mL/min and 
0.5mL/min.  Likewise, 1 day release at 1000 rpm stirring was statistically smaller than at 
700 and 1500 rpm.  These minimums did not seem to indicate a trend within their 
respective parameters. Overall, trends from Experiment 1 did not extrapolate to lower 
or higher ranges in Experiment 2 regarding 1 day release.  However, the constant 
parameters chosen, including polymer type, polymer concentration, SO viscosity, and 
SO volume seemed to have a positive effect on the encapsulation efficiency which 
increased with little variability in Experiment 2.  An increase in encapsulation efficiency 
was observed over the range of increasing stirring speeds which is somewhat consistent 
with Experiment 1.  Encapsulation efficiency at 1000 and 1500 rpm are not statistically 
different than each other but are statistically greater than at 700 rpm which is 
statistically greater than at 500 and 300 rpm.  It is clear that experimental variability 
















SO Infusion Rate 
0.1mL/min 34.7±5.0 101.7±9.1 
0.3mL/min 46.7±9.0 93.4±8.9 
0.5mL/min 39.2±10.0 97.6±6.4 
Stirring Speed 
700rpm 39.2±10.0 97.6±6.4 
1000rpm 31.4±6.0 106.7±6.6 
1500rpm 42.1±2.4 107.1±11.2 
PI Stirring Time 
0min 46.7±9.0 93.4±8.9 















CHAPTER 4. DISCUSSION 
4.1 BSA Release Study 
The summarized BSA release study was conducted in stages with the intent of 
identifying parameters that would decrease burst release, decrease the release rate, or 
increase encapsulation efficiency of protein from biodegradable microparticles.  This 
was done because previous studies had shown that controlled protein release beyond 
one month was very difficult, especially while obtaining high encapsulation 
efficiency37,38,39.  In our laboratory, we had the advantage of experience with polymer 
synthesis, which gave us access to a near infinite number of formulation possibilities.  
For this study, I was able to either find, or synthesize any polymer within the scope of 
our study.  Another advantage that our laboratory has is experience with a hydrogel 
template method for microparticle fabrication.  In contrast to traditional emulsion 
methods, this method allows for quick fabrication and collection of millions of 
microparticles of uniform size.  Our template-based method allows us to use solvents 
such as DX and ACN that are not normally used in emulsion techniques.  Additionally, 
this method allows for solutions of higher polymer concentration and higher viscosity 




The data collected from the BSA release study resulted in a better understanding 
of the major factors that affect protein release.  Results identified polymer type, 
crystallinity, molecular weight, L:G ratio, and solvent as key parameters in controlling 
protein release.  Although previous literature had reported on PLGA degradation 
due to molecular weight and crystallinity, few of them had explored the effect on drug 
release or protein release40, 41.  The current results indicate that polymer crystallinity has 
a large effect on burst release and release rate.  We see that formulations with PLLA or 
PLGA with high L:G ratios perform much better than PLGA with low L:G ratios.  This can 
be mostly attributed to increased hydrophobicity and thus, decreased water infiltration 
in these formulations.  However, PDLLA formulations also performed better than most 
PLGA formulations.  This is likely due to its greater hydrophobicity than PLGA16.  
Therefore, in PLGA formulations, we can credit the wide variety of BSA release rates to 
the wide variety of possible compositions, crystallinities, and hydrophobicities.  Release 
profiles showed that PLGA formulations with 85:15 L:G ratios performed much better 
than 50:50, 60:40, and 75:25 L:G ratios.  No notable differences were observed between 
the other L:G ratios.  Regrettably, very few 75:25 PLGAs were used in this study and 
better conclusions regarding L:G ratio may have been drawn if they had.  However, it is 
clear that in order to achieve linear plateau phase release and low burst release, PLGA 
L:G ratio of 85:15 or above is the best choice.   
We can use these trends in order to customize release profiles for different 
protein drugs.  This study has shown that we can release protein with burst release from 
5.4% to 97%.   We also have the ability to customize the plateau release phase.  We 
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have seen formulations that release from 0.07% to 0.51% per week.  For a 35mg 
microparticle dose loaded with 20% protein, this means we can deliver from 4.9µg to 
35.7µg per week with a zero-order profile.  In this study, we have also identified 
formulations that can release gradually for 3 months to over 1.5 years.  This illustrates 
the wide range of applications that are possible by simply changing input parameters.   
Formulations with DX as a solvent resulted in lower burst release than their DCM 
counterparts for three polymers.  No other trends were observed regarding solvent.  
This may be an area of interest in a future study.  It is possible that the drying properties 
of DX, in that it has a high boiling point (101.1 oC) allows the polymer to collapse within 
the microfabrication template, resulting in lower burst.  However, no notable trends 
were observed regarding the steady state release rate after burst release.  No published 
works could be found concerning the behavior of PLGA dissolved in DX and DCM.   
Although I was able to collect valuable data and draw meaningful conclusions 
from the BSA release study, it was not without its limitations.  Firstly, randomization of 
the formulations would be ideal for better statistical analysis.  Unfortunately, the long-
term implications and goals of this study changed and evolved as more formulations 
were added.  The formulation process was largely a trial-and-error process at the start in 
order to determine possible extended release formulations.  The second limitation of 
the study is the number of replications for each formulation.  In an ideal study, at least 
three lots of microparticles would have been fabricated for each formulation.  This 
would help to give a better understanding of the consistency of the fabrication process.  
This limitation became evident when analyzing the total protein release data.  Total 
49 
 
protein ranged from 70% to 135% of the theoretical totals with an average of 94%±12%.  
These results highlight another limitation which is the experimental variation associated 
with the microparticle fabrication process and BCA assay analysis.  It may be possible to 
mitigate some of this variation in the future by using more advanced release analysis 
such as HPLC and by tightly controlling the fabrication environment.  These limitations 
added to the sample variability but did not alter the key conclusions.  Finally, BSA acted 
as a model protein in this study but clearly cannot be used to predict the release 
characteristics of all proteins.  A future study would benefit from using more than one 
or several proteins of varying molecular weights, conformations, and hydrophobicities.   
 
4.2 BSA Micronization 
The aim of the current micronization study was to identify a method of bench 
grinding that could be used to micronize protein to below 10µm in order to preserve 
activity.  In the BSA release study that was conducted prior to the solid-form 
micronization study, BSA was precipitated using zinc chloride and acetone.  This resulted 
in very small solid precipitate particles (less than 5µm) but it was later identified that 
this method caused protein unfolding and deactivation.  A study using botulinum toxin 
that is not included in this work confirmed that the protein had denatured.  The current 
micronization study was able to identify a low cost, ball grinding method that output 
sub-10µm particles and retained activity.  Similar size reduction can be obtained using 
techniques like jet milling but at a much higher cost42.  Activity was also confirmed using 
botulinum toxin in a study that was omitted from this work.  The cost of the bench-
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made ball grinding system is approximately $500.  This is much less than commercial 
grinding systems such as jet mills, and planetary ball mills which can cost $5,000 to 
$50,000 to obtain similar results.  It was also observed that addition of PVP may be 
helpful to reduce aggregation and, ultimately, particle size.  Limitations for this study 
included low protein recovery and no nano-scale size reduction.  Due to static forces, 
protein stuck to the grinding balls and the grinding jar, making it difficult to collect all of 
the protein.  It was possible to collect approximately 85% of the protein but 100% 
recovery would be preferred if using an expensive protein.  Some expensive grinding 
equipment can output submicron particles and might be preferred if such sizes were 
needed.  However, for studies in which sub-10µm particles are sufficient, the current 
bench method should work well.   
 
4.3 Coacervation Study 
The objective of this experiment was to use the information from the 
microparticle BSA release study in conjunction with published coacervation data to 
fabricate PLGA coated microspheres in order to maximize encapsulation and minimize 
burst release.  Previous authors have attempted to use coacervation to trap the drug 
inside the microspheres, similar to this study43,44,45.  In order to optimize the 
microspheres, the study was designed to evaluate several process parameters.  Results 
indicated that it was, in fact, possible to load 50% BSA with nearly 100% encapsulation 
efficiency into microspheres. Unfortunately, the microspheres were not able to retain 
the BSA for very long.  The minimum 1 day release for 50% loaded microspheres was 31% 
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compared to 19% in 10% loaded microfabricated particles.  This is likely due to well-
documented porosity issues that arise in microsphere fabrication46,47,48.  It was observed 
that SO infusion rate, SO viscosity, stirring rate, and SO volume may have effects on 
burst release, however, these effects did not have a predictable relationship.  There may 
be a sweet spot in which burst release and encapsulation efficiency are optimized.  
These parameters should be observed more extensively in a future study.   From this 





CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS 
From this research, I was able to identify several formulation parameters that have 
profound effects on the release of protein from biodegradable microparticles.  It is clear 
that properties of the polymer had the most profound effect.  The burst release was 
primarily controlled by the polymer type (PLLA, PDLLA, PLGA) with PLLA polymers having 
the lowest release on average. Release rate during the plateau phase seemed to be 
controlled, also, by the polymer type with PLLA having the lowest average.  For PLGA 
polymers, high L:G ratios (85:15) had lower burst and linear plateau phase.  It was 
observed that there is a molecular weight sweet spot (30-100kDa) in which burst release 
and release rate are optimized.  Overall, the BSA release study identified a new set of 
tools that can be used to customize release profiles for protein drugs.   
A new micronization method for lyophilized proteins was also identified.  This 
grinding method provides a low-cost effective option for obtaining active sub-10µm 
protein particles.  It was also possible to load these particles successfully into 
microspheres by coacervation. With nearly 100% encapsulation efficiency, this 
experiment identified coacervation as a feasible protein encapsulation method and 
validated the micronization method.
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 In summary, the results from this work will, hopefully, act as a starting point for 
future research in protein therapeutics.  Future studies should expand upon the 
conclusions drawn here and should try to identify crystal structure and organization of 
biodegradable polymers to better understand their effect on release.  In addition, the 
methods used in this research should also be applied to more proteins in order to 
assess its broad applicability.  It should be emphasized that not all protein encapsulation 
techniques will yield the same results and that post fabrication processing should be 
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